Catheterized guinea pigs infected with Ebola Zaire virus allows safer sequential sampling to determine the pharmacokinetic profile of a phosphatidylserine-targeting monoclonal antibody

Antiviral Research

Volumn 97, Issue 2, 2013, Pages 108-111

  Dowall, Stuart ^a   Taylor, Irene ^a   Yeates, Paul ^a   Smith, Leonie ^a   Rule, Antony ^a   Easterbrook, Linda ^a   Bruce, Christine ^a   Cook, Nicola ^a   Corbin Lickfett, Kara ^b   Empig, Cyril ^b   Schlunegger, Kyle ^b   Graham, Victoria ^a   Dennis, Mike ^a   Hewson, Roger ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b Peregrine Pharmaceuticals Inc   (United States)

Author keywords

Catheterized; Ebola; Model; Pharmacokinetic

Indexed keywords

BAVITUXIMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATHETERIZATION; CONTROLLED STUDY; DRUG HALF LIFE; EBOLA HEMORRHAGIC FEVER; EXPERIMENTAL GUINEA PIG; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; EBOLAVIRUS; GUINEA PIGS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGIC FACTORS; PHOSPHATIDYLSERINES;

ANIMALIA; CAVIA; EBOLA VIRUS;

EID: 84871894016     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.11.003     Document Type: Article

References (23)

1. Bente D., Gren J., Strong J.E., Feldmann H. Disease modeling for Ebola and Marburg viruses. Dis. Model Mech. 2009, 2:12-17.
2. Borio L., Inglesby T., Peters C.J., Schmaljohn A.L., Hughes J.M., Jahrling P.B., Ksiazek T., Johnson K.M., Meyerhoff A., O'Toole T., Ascher M.S., Bartlett J., Breman J.G., Eitzen E.M., Hamburg M., Hauer J., Henderson D.A., Johnson R.T., Kwik G., Layton M., Lillibridge S., Nabel G.J., Osterholm M.T., Perl T.M., Russell P., Tonat K. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002, 287:2391-2405.
3. Bray M. Defense against filoviruses used as biological weapons. Antiviral Res. 2003, 57:53-60.
4. Chepurnov A.A., Zubavichene N.M., Dadaeva A.A. Elaboration of laboratory strains of Ebola virus and study of pathophysiological reactions of animals inoculated with these strains. Acta Trop. 2003, 87:321-329.
5. Connolly B.M., Steele K.E., Davis K.J., Geisbert T.W., Kell W.M., Jaax N.K., Jahrling P.B. Pathogenesis of experimental Ebola virus infection in guinea pigs. J. Infect. Dis. 1999, 179(Suppl. 1):S203-S217.
6. Graham M.L., Mutch L.A., Rieke E.F., Dunning M., Zolondek E.K., Faig A.W., Hering B.J., Schuurman H.J. Refinement of vascular access port placement in nonhuman primates: complication rates and outcomes. Comp. Med. 2010, 60:479-485.
7. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
8. Holmes A.M., Creton S., Chapman K. Working in partnership to advance the 3Rs in toxicity testing. Toxicology 2010, 267:14-19.
9. Huang X., Bennett M., Thorpe P.E. A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice. Cancer Res. 2005, 65:4408-4416.
10. Jahrling P.B., Hesse R.A., Rhoderick J.B., Elwell M.A., Moe J.B. Pathogenesis of a pichinde virus strain adapted to produce lethal infections in guinea pigs. Infect. Immun. 1981, 32:872-880.
11. Kitagawa H., McComb G., Ford E., Atkinson J.B. Proximal and distal cannulation of the internal jugular vein for ECMO in a primate. J. Pediatr. Surg. 1992, 27:1189-1191.
12. Mir H.M., Birerdinc A., Younossi Z.M. Monoclonal and polyclonal antibodies against the HCV envelope proteins. Clin. Liver Dis. 2009, 13:477-486.
13. Pai J.C., Sutherland J.N., Maynard J.A. Progress towards recombinant anti-infective antibodies. Recent Pat. Antiinfect Drug Discov. 2009, 4:1-17.
14. Ryabchikova E., Kolesnikova L., Smolina M., Tkachev V., Pereboeva L., Baranova S., Grazhdantseva A., Rassadkin Y. Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis. Arch. Virol. 1996, 141:909-921.
15. Sakamoto N., Watanabe M. New therapeutic approaches to hepatitis C virus. J. Gastroenterol. 2009, 44:643-649.
16. Scalese R.J., DeForrest J.M., Hammerstone S., Parente E., Burkett D.E. Long term vascular catheterization of the cynomolgus monkey. Lab. Anim. Sci. 1990, 40:530-532.
17. Soares M.M., King S.W., Thorpe P.E. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat. Med. 2008, 14:1357-1362.
18. Subbotina E., Dadaeva A., Kachko A., Chepurnov A. Genetic factors of Ebola virus virulence in guinea pigs. Virus Res. 2010, 153:121-133.
19. Thorpe P.E. Targeting anionic phospholipids on tumor blood vessels and tumor cells. Thromb. Res. 2010, 125(Suppl. 2):S134-S137.
20. Tomillero A., Moral M.A. Gateways to clinical trials. Methods Find. Exp. Clin. Pharmacol. 2008, 30:643-672.
21. Tomillero A., Moral M.A. Gateways to clinical trials. Methods Find. Exp. Clin. Pharmacol. 2009, 31:661-700.
22. Volchkov V.E., Chepurnov A.A., Volchkova V.A., Ternovoj V.A., Klenk H.D. Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology 2000, 277:147-155.
23. Wojnicki F.H., Bacher J.D., Glowa J.R. Use of subcutaneous vascular access ports in rhesus monkeys. Lab. Anim. Sci. 1994, 44:491-494.